drugset
drugset / Trial / NCT07476872

Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

NCT07476872 ↗

Phase 1/2 Not yet recruiting 33 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety and efficacy of Gecacitinib in patients with steroid-refractory/dependent active chronic graft versus host disease (cGVHD).

Timeline

Start
2026-03-16
Primary completion
2027-11-01
Completion
2028-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gecacitinib Unknown 50 mg —
Subject Gecacitinib Unknown 100 mg —
Subject Gecacitinib Unknown 150 mg —

Indications

chronic graft versus host disease